Genomic Tests
Comprehensive Genomic Profiling using Next-Generation Sequencing
Solid Tumors
Next Generation Sequencing DNA & RNA Testing
Hematologic Tumors
Next Generation Sequencing DNA & RNA Testing
Solid Tumors
Solid Tumor
Profile
434
Genes
-
TAT
5-7 Days
-
Indications
All solid tumors:
Mutations in 434 genes,
copy number variation and chromosomal structural abnormalities,
TMB, MSI, HRD–
-
Sample Type
FFPE
-
Sample Requirements
1 H&E slide and 6-8 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative
-
Results Reported
DNA
- Diagnostic
- Therapeutic
- Prognostic
- Heterogeneity
- Clinical Trial Matching
Read More
Learn more about this test
Solid Tumor Fusion / Expression Profile
1501
Genes
-
TAT
7-10 Days
-
Indications
ALL Solid tumors:
Fusion: ALK, ROS1, RET, NTRK1/2/3, FGFR1/2/3/4, BRAF, CIC, EWSR1 and other sarcoma genes
Expression: PD-L1, MYC, CCND1, MET, FGFR1/2/3/4, Ki67,
ERBB2, MDM2
Alternative splicing: MET exon 14 skipping, EGFR vIII , NTRK
Mutations in all 1400 genes -
Sample Type
FFPE
-
Sample Requirements
1 H&E slide and 6-8 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative
-
Results Reported
RNA
- Diagnostic
- Therapeutic
- Prognostic
- Heterogeneity
- Clinical Trial Matching
Read More
Learn more about this test
Solid Tumor
Profile Plus
434/1501
Genes
-
TAT
7-10 Days
-
Indications
ALK, ROS1, RET, NTRK1/2/3, BRAF, CIC, EWSR1, PD-L1,
MET exon 14 skipping and various alternative splicing,
MET, HER2,
EGFR amplification,
PIK3CA, PTEN, AKT1, RAS, HRD–
-
Sample Type
FFPE
-
Sample Requirements
1 H&E slide and 6-8 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative
-
Results Reported
DNA+RNA
- Diagnostic
- Therapeutic
- Prognostic
- Heterogeneity
- Clinical Trial Matching
Read More
Learn more about this test
PLUS
Liquid Trace
Solid Tumor
284/1501
Genes
-
TAT
5-7 Days
-
Indications
Monitoring therapy,
resistance and relapse–
-
Sample Type
Peripheral blood
-
Sample Requirements
Peripheral blood: 5-10 ml.
EDTA tube preferred -
Results Reported
DNA+RNA
- Monitoring
- Therapeutic
- Prognostic
- Heterogeneity
- Clinical Trial Matching
Read More
Learn more about this test
Liquid Biopsy
Hematology
Hematology
Profile
284
Genes
-
TAT
5-7 Days
-
Indications
MDS, CMML, AML, MPN (JAK2, CALR, MPL), MRD, lymphoma, multiple myeloma, other hematologic diseases
–
-
Sample Type
Bone marrow,
Peripheral blood,
Fresh tissue -
Sample Requirements
Bone marrow: 2ml.
Peripheral blood: 5 ml.
EDTA tube preferred
FFPE: 1 H&E slide and 6-10 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative -
Results Reported
DNA
- Diagnostic
- Therapeutic
- Prognostic
- Heterogeneity
- Clinical Trial Matching
Read More
Learn more about this test
Liquid Trace
Hematology Profile
284/1501
Genes
-
TAT
5-7 Days
-
Indications
Chromosomal abnormalities, gene amplifications, multiple myeloma, lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, MDS, CMML, AML, MPN, MRD, VEXAS syndrome, HPV, EBV
–
-
Sample Type
Peripheral blood
-
Sample Requirements
Peripheral blood: 5-10 ml.
EDTA tube preferred
– -
Results Reported
DNA+RNA
- Diagnostic
- Therapeutic
- Prognostic
- Heterogeneity
- Clinical Trial Matching
Read More
Learn more about this test
Hematology
Profile Plus
284/1501
Genes
-
TAT
7-10 Days
-
Indications
Classification and diagnosis of lymphoma, multiple myeloma, acute lymphoblastic leukemia, acute myeloid leukemia
Includes IgVH
–
-
Sample Type
Bone marrow,
Peripheral blood,
Fresh tissue -
Sample Requirements
Bone marrow: 2ml.
Peripheral blood: 5 ml.
EDTA tube preferred
FFPE: 1 H&E slide and 6-10 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative -
Results Reported
DNA+RNA
- Diagnostic
- Therapeutic
- Prognostic
- Heterogeneity
- Clinical Trial Matching
Read More
Learn more about this test
PLUS